Paragon 28 (FNA) Q1 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2024 earnings summary
31 Oct, 2026Executive summary
Q1 2024 revenue reached a record $61.1M, up 17.4% reported and constant currency YoY; growth spanned all five foot-and-ankle subsegments.
FY 2024 revenue guidance was reaffirmed at $249M–$259M, implying 15.1%–19.7% YoY growth.
Financial highlights
Gross profit rose 13% to $48.9M; gross margin fell to 80.0% from 82.9% YoY.
Operating expenses increased 21.5% to $61.8M; operating loss widened to $12.9M from $7.7M.
Net loss was $15.2M versus $9.1M; adjusted EBITDA loss was $5.5M versus $1.4M, including a $0.5M non-cash fair-value adjustment.
One fewer billing day created an estimated 200 bps revenue headwind.
Outlook and guidance
FY 2024 revenue guidance assumes normalized seasonality, a stabilized supply chain and current foreign-currency translation rates.
U.S. growth drivers include new products, sales-force expansion and productivity, customer expansion and penetration; international outlook cites U.K. and Australia growth and momentum in other markets.
Existing cash, available borrowing capacity and expected revenues were expected to fund capital requirements and operations for at least 12 months.
Latest events from Paragon 28
- FY 2023 revenue rose 19.3%; FY 2024 guidance reaches $259M amid inventory-driven margin pressure.FNA
Q4 2023 - Strong product innovation and operational discipline position the company for profitable growth in 2025.FNA
Piper Sandler 36th Annual Healthcare Conference - Q3 revenue up 18.1% with first positive Adjusted EBITDA since IPO, but net loss and risks persist.FNA
Q3 2024 - Transformative product launches and digital platforms drive growth and efficiency targets.FNA
Canaccord Genuity 44th Annual Growth Conference - Q2 revenue up 19.6%–20% to $61M; 2024 guidance narrowed, efficiency plan launched.FNA
Q2 2024 - Robust growth and innovation drive leadership ambitions in the foot and ankle market.FNA
43rd Annual J.P. Morgan Healthcare Conference 2025